Bayer defeats Sandoz challenge to patents for blood thinner Xarelto

Intellectual Property 2023-11-02 9:41 pm By Cindy Cameronne | Sydney

Please login to bookmark

Novartis unit Sandoz AG has lost its bid to revoke Bayer’s patents for its top-selling blood clot drug Xarelto and has been barred from selling generic versions of the medication after a judge found the German pharma giant’s patents were valid.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au